Latest

Trackers› Clinical trials› Fuzhou

Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC

19052

Studies in scope

all four open statuses

11786

Recruiting now

open to new participants

2009

Lead sponsors

across recruiting studies

Top sites

Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343

Trials with a site in Fuzhou

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Active, closed

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02966756Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

AbbVie

Phase 2

66

Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha

2017-10-12

Active, closed

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451Hepatocellular Carcinoma

DrugsSorafenib·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

1,324

Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou

2017-10-11

Active, closed

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

NCT03221036Moderately to Severely Active Ulcerative Colitis

DrugVedolizumab

Takeda

Phase 3

392

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Meizhou

2017-08-03

Active, closed

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997Breast Cancer

DrugAbemaciclib

Eli Lilly and Company

Phase 3

5,637

Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Jinan

2017-07-12

Active, closed

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616Non Small Cell Lung Cancer NSCLC

DrugsAbraxane·Tremelimumab·Durvalumab·Pemetrexed

AstraZeneca

Phase 3

1,186

Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei

2017-06-01

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116Locally Advanced Solid Tumors, Metastatic Solid Tumors

DrugRepotrectinib

Turning Point Therapeutics, Inc.

Phase 1/2

500

Beijing, Daping, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Shatin

2017-03-07

Active, closed

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523Acute Myeloid Leukemia (AML)

DrugsAzacitidine·Venetoclax

AbbVie

Phase 3

443

Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Changchun, Shanghai

2017-02-02

Recruiting

Cohort Study in Fujian Province

NCT06102187Chronic Disease

Fujian Provincial Hospital

Observational

150,000

Fuzhou

2017-01-01

Active, closed

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

NCT02763566Breast Cancer

DrugsAnastrozole·Abemaciclib·Letrozole·Fulvestrant

Eli Lilly and Company

Phase 3

463

Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou

2016-12-05

Active, closed

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT02767804Non-small Cell Lung Cancer

DrugsEnsartinib·Crizotinib

Xcovery Holdings, Inc.

Phase 3

290

Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing

2016-06

Active, closed

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

NCT02455141Breast Neoplasm

Shanghai Jiao Tong University School of Medicine

Phase 3

786

Fuding, Fuzhou, Quanzhou, Foshan, Guangzhou, Harbin, Jiangyin, Suzhou

2016-03

Active, closed

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318Prostate Cancer

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,052

Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai

2015-11-27

Active, closed

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823Breast Cancer

AstraZeneca

Phase 3

1,837

Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing

2014-04-22

Recruiting

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

Janssen Research & Development, LLC

Phase 3

700

Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shanxi, Suzhou

2013-09-09

Recruiting

Registry of Multicenter Brain-Heart Comorbidity in China

NCT05961748Ischemic Heart Disease, Cardiac Arrest, Atrial Fibrillation, Heart Failure

Beijing Tiantan Hospital

Observational

100,000

Beijing, Fuzhou, Xiamen, Shenzhen, Harbin, Zhengzhou, Shanghai, Shanxi

2012-01-01

By invitation

A Registered Observational Cohort Study of Myotonic Dystrophy Type 1

NCT06979024Myotonic Dystrophy Type 1 (DM1)

First Affiliated Hospital of Fujian Medical University

Observational

300

Fuzhou

2008-01

Recruiting

A Registered Cohort Study on FSHD1

NCT04369209Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)

Ning Wang, MD., PhD.

Observational

1,000

Fuzhou

2001-01

Recruiting

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Medtronic

Observational

20,000

Beijing, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming

1983-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou?page=11

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,018 of those studies with a site in Fuzhou.

How many clinical trials are recruiting in Fuzhou?

594 of the 1,018 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 114 have not yet opened recruitment, 287 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.